Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06804096
PHASE4

Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)

Sponsor: Dr. Md. Alimur Reza

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.

Official title: Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP): A Randomized Controlled Trial

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2025-02-20

Completion Date

2025-12-01

Last Updated

2025-07-11

Healthy Volunteers

No

Interventions

DRUG

Faropenem

Tab. Faropenem 200mg three times daily

DRUG

Co-amoxiclav

Tab. Co-Amoxiclav 625mg three times daily

DRUG

Clarithromycin 500 mg

Tab. Clarithromycin 500mg two times daily

Locations (2)

Popular Medical College & Hospital

Dhaka, Dhaka Division, Bangladesh

Shaheed Suhrawardy Medical College & Hospital

Dhaka, Dhaka Division, Bangladesh